Research

Dr. Stabile’s research is focused on how estrogen interacts with the immune system to play a role in the development of lung cancer and in metastases. Her recent studies show that estrogen activity on non-tumor cells within the lung tumor microenvironment plays an important role in tumor progression by promoting a protumor immunosuppressive phenotype that allows the tumor to evade the immune system.
Learn More

2025 Research Update

Continued progress in understanding lung cancer in never smokers, especially women, a group that now represents a growing share of new diagnoses. The work focuses on identifying environmental chemical exposures linked to cancer risk, clarifying how hormones and immune responses differ between men and women, and improving detection and treatment of brain metastases. The research also highlights practical advances, including better methods to identify hard-to-detect genetic changes, tools to predict which patients are at highest risk for brain spread, and new approaches to guide targeted therapies. Together, this research aims to fill important gaps in knowledge and support more effective, personalized care for lung cancer patients.

2024 Research Update

In 2024, significant progress was made in understanding lung cancer risk, biology, and treatment outcomes, particularly among women and never smokers, focusing on the distinct disease characteristics and risk factors of lung cancer in this group. This research leverages cutting-edge technologies to explore biological networks, environmental exposures, and sex differences, aiming to improve care through personalized treatment strategies, including advancements in brain metastasis prediction and MET pathway targeting.

2023 Research Update

This update includes findings that were published in the journal Scientific Reports. Furthermore, learn more about a research trial that is now accepting patients and a brain metastasis prediction model that is in development.

2022 Research Update

An update on Dr. Stable’s research including new grants and a drug trial that is focused on MET amplification. Biomarker testing for Elizabeth in November 2022 showed MET is the new driver of her ALK+ cancer progression.